Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
House committee backs bill protecting clinicians who prescribe FDA‑approved drugs for off‑label uses, drawing controversy
Summary
House Committee of the Whole recommended passage of HB164 to protect prescribers and pharmacists dispensing FDA‑approved drugs for off‑label indications, while excluding controlled substances, abortions and gender‑transition prescriptions for minors; critics said the bill could override employer policies and create legal ambiguities.
The Wyoming House Committee of the Whole recommended passage of House Bill 164, a measure that would expressly allow prescribers and pharmacists to provide FDA‑approved prescription drugs for off‑label indications and limit professional or disciplinary action solely for using an approved drug for an unapproved indication. The committee reported the bill do pass (committee vote recorded 30‑21).
Representative Gary Brown, the bill sponsor, described the measure as protecting prescribers who prescribe FDA‑approved drugs for uses that are not the drug’s originally approved indication. “A prescriber may lawfully prescribe a United States Food and Drug Administration approved prescription…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
